RxDoctor Payments Data

Chaim Silberberg, MD

Internal Medicine · Spring Valley, NYNPI 1265473540

Payments from drug & device makers

$210in general payments, 2019–2025

Across 5 payments — averaging $41.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$125
  • Acadia Pharmaceuticals Inc$26
  • AstraZeneca$22
  • Otsuka America Pharmaceutical, Inc.$20
  • Mylan Specialty L.p.$18

What the payments were for

  • Food & beverage$210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$210 in reported general payments places this provider in the 50th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$347,605
Medicare patients
999
Services billed
3,314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,229$358,529
JanuviaSitagliptin Phosphate508$146,439
Invega SustennaPaliperidone Palmitate30$82,659
XareltoRivaroxaban277$81,230
JardianceEmpagliflozin211$68,189
EntrestoSacubitril/Valsartan130$44,406
SantylCollagenase Clostridium Hist.90$42,339
TrulicityDulaglutide37$35,631
MyrbetriqMirabegron151$35,090
Divalproex Sodium458$27,733
FarxigaDapagliflozin Propanediol86$27,441
OzempicSemaglutide26$26,757
Atorvastatin Calcium1,626$25,472
ProcritEpoetin Alfa32$25,225
NuedextaDextromethorphan Hbr/Quinidine26$20,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$22$36,163111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Spring Valley

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →